BCL2 and B-cell chronic lymphocytic leukemia: To overcome this toxicity, the first-in-class orally bioavailable Bcl-2-selective BH3 mimetic ABT-199 was developed and thus far has shown very promising antitumor activity while sparing platelets in chronic lymphoid leukemia (CLL) and B-cell lymphomas, including MCL [10, 11].